Japanese encephalitis vaccine

A Japanese encephalitis vaccine is a vaccine against infection with the Japanese encephalitis virus .

properties

The first two Japanese encephalitis vaccines were developed in the 1950s and were inactivated vaccines. The vaccine JE-Vax was produced in cell cultures of murine neurons until 2005 (vaccine strain Nakayama or Beijing-3 ). The Beijing-1 vaccine strain was used in China from 1968 to 2005.

Today's Japanese encephalitis vaccines are either live attenuated vaccines or inactivated vaccines. In the US, only the inactivated vaccine ( Ixiaro ) has been approved for people over the age of 17 since 2009 and for people two months and over since 2013. Ixiaro (synonym JEspect , vaccine strain IC51 ) was approved in Europe, Australia and the USA in 2009 and is based on the vaccine strain SA14-14-2 cultivated in Vero cells . This vaccine is given twice. There are also attenuated vaccines SA14-14-2 (vaccine strain SA14-14-2 , China, 1988) and ImoJEV (vaccine strain ChimeriVax-JE ). ImoJEV is a combination vaccine with a yellow fever vaccine and was approved in Australia in 2009.

Inactivated Japanese Encephalitis Vaccine is on the World Health Organization's Essential Medicines List .

immunology

After a double vaccination, vaccinated people develop measurable titers for neutralizing antibodies that protect against re-infection with Japanese encephalitis viruses for a year.

Side effects

Adverse drug effects from Japanese encephalitis vaccines include pain, redness, swelling and muscle pain at the injection site, and fever.

Contraindications

Contraindications for Japanese encephalitis vaccines include: B. Pregnancy and allergic reactions to vaccine ingredients.

Trade names

Trade names for Japanese encephalitis vaccines are e.g. B. Ixiaro ( JEspect in Australia), SA14-14-2 and ImoJEV .

literature

• DM Knipe, Peter M. Howley , DE Griffin, (Eds.): Fields Virology. 5th edition, Lippincott Williams & Wilkins, Philadelphia 2007, ISBN 978-0-7817-6060-7 .

Individual evidence

1. ↑ ^{a b} Halstead SB, Thomas SJ: Japanese encephalitis: new options for active immunization . In: Clin Infect Dis . 50, No. 8, April 2010, pp. 1155-64. doi : 10.1086 / 651271 . PMID 20218889 .
2. ↑ ^{a b c} Centers for Disease Control and Prevention : CDC: Japanese Encephalitis Vaccine .
3. ↑ Schiøler KL, Samuel M, Wai KL: Vaccines for preventing Japanese encephalitis . In: Cochrane Database Syst Rev . No. 3, 2007, p. CD004263. doi : 10.1002 / 14651858.CD004263.pub2 . PMID 17636750 .
4. ↑ Halstead SB, Thomas SJ: New Japanese encephalitis vaccines: alternatives to production in mouse brain . In: Expert Rev Vaccines . 10, No. 3, March 2011, pp. 355-64. doi : 10.1586 / erv.11.7 . PMID 21434803 .
5. ↑ WHO Model List of Essential Medicines . In: World Health Organization . October 2013. Retrieved April 22, 2014.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !